Why is this study being conducted?
The purpose of this study is to evaluate safety and effectiveness of a potential new COVID-19 and Influenza combination vaccine and a standalone influenza vaccine.
Who is eligible to participate in this study?
You may be eligible if you:
- Are aged 65 years or older
- Have been vaccinated against COVID-19
- Are able to attend all scheduled study visits
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be about 6 months and you will have about 6 trial visits (including onsite visits and phone calls).
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will receive one vaccine at the first study visit.
You will have safety phone calls throughput the study.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Ting Yu
To learn more about this clinical trial, please contact:
Ting Yu, Clinical Trial Coordinator.
07 5678 0112 clinicaltrialunit@griffith.edu.au
This trial has been approved by an independent ethics committee and GU HREC (2024/618).
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials